Literature DB >> 8132350

Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease.

H K Guttormsen1, L M Wetzler, C O Solberg.   

Abstract

We have determined the amounts of specific anti-class 1 outer membrane protein antibodies in sera from 25 patients during the course of systemic meningococcal disease, using purified class 1 protein as the sensitizing antigen in an enzyme-linked immunosorbent assay. The class 1 protein was obtained from a variant of strain 44/76 (B:15:P1.7,16) lacking class 3 and class 4 outer membrane proteins. Specific anti-class 1 (serosubtype P1.7,16) outer membrane protein immunoglobulin G (IgG) antibody levels increased significantly in 12 patients (12 of 25; 48%), regardless of the serotype of the infecting strain, indicating that the antibodies reacted in part with epitopes not determined by the monoclonal antibodies used for serotyping. Most patients had low levels of anti-class 1 IgG antibodies during the acute illness. The antibody levels peaked during the second week of disease and returned to near baseline levels in sera collected 6 weeks to 12 months after the onset of the disease. The majority of the specific anti-class 1 IgG antibodies bound to surface-exposed epitopes on whole bacteria and belonged to the IgG1 and IgG3 subclasses. Anti-class 1 IgA and IgM antibodies were not detected in any of the patient sera. Prior to disease, seven patients had been immunized with a meningococcal outer membrane vesicle vaccine developed from strain 44/76 (P1.7,16). None of these patients was infected with meningococcal strains containing class 1 protein homologous or partly homologous to that of the vaccine strain, indicating serosubtype-specific protection. The highest anti-class 1 IgG antibody peak levels were seen in immunized patients infected with strains of heterologous serotype, suggesting an anamnestic response. However, these patients were not protected from meningococcal disease after immunization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132350      PMCID: PMC186299          DOI: 10.1128/iai.62.4.1437-1443.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  The analysis of lipopolysaccharide (endotoxin) in meningococcal polysaccharide vaccines by silver staining following SDS-polyacrylamide gel electrophoresis.

Authors:  C M Tsai
Journal:  J Biol Stand       Date:  1986-01

2.  Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in The Gambia, West Africa.

Authors:  B A Crowe; R A Wall; B Kusecek; B Neumann; T Olyhoek; H Abdillahi; M Hassan-King; B M Greenwood; J T Poolman; M Achtman
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

3.  Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.

Authors:  R E Mandrell; W D Zollinger
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

4.  IgG subclasses in bacterial infections.

Authors:  L Hammarström; C I Smith
Journal:  Monogr Allergy       Date:  1986

5.  Serum antibodies to cross-reactive Neisseria outer membrane antigens in healthy persons and patients with meningococcal disease.

Authors:  J A Maeland; E Wedege
Journal:  APMIS       Date:  1989-09       Impact factor: 3.205

6.  Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.

Authors:  E Rosenqvist; S Harthug; L O Frøholm; E A Høiby; K Bøvre; W D Zollinger
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

7.  Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development.

Authors:  K Saukkonen; H Abdillahi; J T Poolman; M Leinonen
Journal:  Microb Pathog       Date:  1987-10       Impact factor: 3.738

8.  Sequence of the structural gene (rmpM) for the class 4 outer membrane protein of Neisseria meningitidis, homology of the protein to gonococcal protein III and Escherichia coli OmpA, and construction of meningococcal strains that lack class 4 protein.

Authors:  K P Klugman; E C Gotschlich; M S Blake
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

9.  Colony morphology of piliated Neisseria meningitidis.

Authors:  M S Blake; C M MacDonald; K P Klugman
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

10.  Characterization and specificity of antibodies to protein I of Neisseria gonorrhoeae produced by injection with various protein I-adjuvant preparations.

Authors:  L M Wetzler; M S Blake; E C Gotschlich
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  16 in total

1.  Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.

Authors:  Kay O Johswich; Shannon E McCaw; Lea Strobel; Matthias Frosch; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2.

Authors:  N Bhasin; Y Ho; L M Wetzler
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis.

Authors:  T F Murphy; C Kirkham; E DeNardin; S Sethi
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

6.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

7.  Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.

Authors:  F Oftung; L M Naess; L M Wetzler; G E Korsvold; A Aase; E A Høiby; R Dalseg; J Holst; T E Michaelsen; B Haneberg
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

8.  Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.

Authors:  L M Naess; F Oftung; A Aase; L M Wetzler; R Sandin; T E Michaelsen
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

9.  Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

10.  Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst.

Authors:  R Bjerknes; H K Guttormsen; C O Solberg; L M Wetzler
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.